Radiobiological Model in Radiotherapy Planning for Prostate Cancer Treatment

Authors: Pradip Deb

Abstract:

Quantitative radiobiological models can be used to assess the optimum clinical outcome from sophisticated therapeutic modalities by calculating tumor control probability (TCP) and normal tissue complication probability (NTCP). In this study two 3D-CRT and an IMRT treatment plans were developed with an initial prescription dose of 60 Gy in 2 Gy/fraction to prostate. Sensitivity of TCP and Complication free tumor control probability (P+) to the different values of α/β ratio was investigated for various prescription doses planned to be delivered in either a fixed number of fractions (I) or in a fixed dose per fraction (II) in each of the three different treatment plans. High dose/fraction and high α/β value result in comparatively smaller P+ and IMRT plans resulted in the highest P+, mainly due to the decrease in NTCP. If α/β is lower than expected, better tumor control can be achieved by increasing dose/fraction but decreasing the number of fractions.

Keywords: Linear Quadratic Model, TCP, NTCP, α/β ratio.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1106779

References:

[1] Fowler, J.F., Nuclear particles in cancer treatment. Medical physics handbooks. 1981, Bristol, UK: Adam Hilger Ltd.
[2] Hirst, D.G., The importance of radiobiology to cancer therapy: current practice and future perspectives. Clinical Oncology, 2007. 19: p. 367- 369.
[3] Pavone-Macaluso, M., Patient selection criteria for surgery, in Radiotherapy of prostate cancer, C. Greco and M. J. Zelefsky, Editors. 2000, Harwood Academic Publishers: Amsterdam, The Netherlands. p. 69-74.
[4] Small, W., Jr. and G. Woloschak, Introduction, in Radiation Toxicity A Practical Guide, W. Small, Jr. and G. Woloschak, Editors. 2006, Springer: Chicago, IL, USA.
[5] Hanks, G.E., et al., Conformal technique dose escalation for prostate cancer: Chemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen >10 ng/ml. International Journal of Radiation Oncology Biology Physics, 1996. 35: p. 861-868.
[6] Leibel, S.A., et al., Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: Preliminary results of a phase I dose-escalation study. International Journal of Radiation Oncology Biology Physics, 1994. 28: p. 55-65.
[7] Perez, C.A., et al., Three-dimensional conformal therapy (3-D CRT) and potential for intensity-modulated radiation therapy in localized carcinoma of prostate. In The Theory and Practice of Intensity Modulated Radiation Therapy. E.S. Sternick, Editor. 1997 Advanced Medical Publishing. Madison, WI, USA. p. 199-217.
[8] Perez, C.A. and J. Michalski, Outcome of external-beam radiation therapy for localized carcinoma of the prostate (stages T1B, T2, and T3). in Radiotherapy of prostate cancer, C. Greco and M.J. Zelefsky, Editors. 2000, Harwood academic publishers: Amsterdam, The Netherlands. p. 155-184.
[9] del Regato, J.A., A.H. Trailins, and D.D. Pittman, Twenty years followup of patients with inoperable cancer of the prostate (stage C) treated by radiotherapy: Report of a national cooperative study. International Journal of Radiation Oncology Biology Physics, 1993. 26: p. 197-201.
[10] Prado, K.L., G. Starkschall, and R. Mohan, Three-dimensional conformal radiation therapy. , in Treatment Planning in Radiation Oncology. F.M. Khan, Editor. 2007, Lippincott Williams & Wilkins: Philadelphia, PA, USA. p. 116-141.
[11] Webb, S., The Physics of Conformal Radiotherapy. 1997, Bristol, UK.: Institute of Physics Publishing.
[12] Khan, F.M., The Physics of Radiation Therapy. 3rd ed. 2003, Philadelphia, USA.: Lippincott, Williams and Wilkins.
[13] Dong, L. and R. Mohan, Intensity-modulated radiation therapy physics and quality assurance. in Practical essentials of intensity modulated radiation therapy., K.S.C. Chao, Editor. 2005, Lippincott Williams & Wilkins: Philadelphia, PA, USA. p. 1-19.
[14] Williams, M., A review of intensity modulated radiation therapy: incorporating a report on the seventh education workshop of the ACPSEM - ACT/NSW branch. Australasian Physical & Engineering Sciences in Medicine, 2002. 25(3): p. 91-101.
[15] Bortfeld, T.R., J. Burkelbach, and R. Boesecke, Methods of image reconstruction from projections applied to conformal therapy. . Physics in Medicine and Biology, 1990. 35: p. 1423-1434.
[16] 16. Brahme, A., Optimization of stationary and moving beam radiation therapy techniques. Radiotherapy Oncology, 1988. 12: p. 129-140.
[17] Convery, D.J. and M.E. Rosenbloom, The generation of intensity modulated fields for conformal radiotherapy by dynamic collimation. Physics in Medicine and Biology, 1992. 37: p. 1359-1374.
[18] Holmes, T. and T.R. Mackie, A filtered back projection dose calculation method for inverse treatment planning. Medical Physics, 1994. 21: p. 303-313.
[19] Kallman, P., B. Lind, and A. Ekloff, Shaping of arbitrary dose distribution by dynamic Multileaf collimation. Physics in Medicine and Biology, 1988. 33: p. 1291-1300.
[20] Mageras, G.S. and R. Mohan, Application of fast simulated annealing to optimization of conformal radiation treatment. Medical Physics, 1993. 20: p. 639-647.
[21] Mohan, R., G.S. Mageras, and B. Baldwin, Clinically relevant optimization of 3D conformal treatments. Medical Physics, 1992. 20: p. 933-944.
[22] Rosen, H., R.G. Lane, and S.M. Morrill, Treatment planning optimization using linear programming. Medical Physics, 1991. 18: p. 141-152.
[23] Webb, S., Optimization of conformal dose distributions by simulated annealing. Physics in Medicine and Biology, 1989. 34: p. 1349-1370.
[24] Fowler, J.F., Radiobiological principles guiding the management of prostate cancer., in Radiotherapy of Prostate Cancer., C. Greco and M.J. Zelefsky, Editors. 2000, Harwood Academic Publishers: The Netherlands. p. 131-145.
[25] Kutcher, G.J., Quantitative plan evaluation: TCP/NTCP models. , in 3-D Conformal Radiotherapy A New Era in the Irradiation of Cancer, J.L. Meyer and J.A. Purdy, Editors. 1996, Karger: Basel, Switzerland. p. 67- 80.
[26] Kutcher, G.J., Quantitative plan evaluation, in Advances in Radiation Oncology Physics Dosimetry, Treatment Planning, and Brachytherapy., J.A. Purdy, Editor. 1990, American Association of Physicists in Medicine: Kansas, USA. p. 998-1021.
[27] Haken, R.K.T. and M.L. Kessler, Quantitative tools for plan evaluation, in General Practice of Radiation Oncology Physics in the 21st Century., A.S. Shiu and D.E. Mellenberg, Editors. 2000, Medical Physics Publishing: Illinois, USA. p. 17-36.
[28] Niemierko, A., Current status of TCP and NTCP calculations, in 3-D Conformal and Intensity Modulated Radiation Therapy: Physics & Clinical Applications. , J.A. Purdy, et al., Editors. 2001, Advanced Medical Publishing: Madison, WI, USA. p. 95-111.
[29] Wigg, D.R., Applied Radiobiology and Bioeffect Planning. 1st ed. 2001, Madison, Wisconsin, USA: Medical Physics Publishing.
[30] Tubiana, M., J. Dutreix, and A. Wambersie, Introduction to Radiobiology. 1990, Bristol: Taylor & Francis. 97-104.
[31] Barendsen, G.W., Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. International Journal of Radiation Oncology Biology Physics, 1982. 8: p. 1981-1997.
[32] Dale, R.G., The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. British Journal of Radiology, 1985. 58: p. 515-528.
[33] Fowler, J.F., The linear quadratic formula and progress in fractionated radiotherapy: a review. British Journal of Radiology, 1989. 62: p. 679- 694.
[34] Brahme, A., J. Nilsson, and D. Belkic, Biologically optimized radiation therapy. Acta Oncologica, 2001. 40(6): p. 725-734.
[35] Agren, A.K., A. Brahme, and I. Turesson, Optimization of uncomplicated control for head and neck tumors. International Journal of Radiation Oncology Biology Physics, 1990. 19(4): p. 1077-85.
[36] Kallman, P., A. Agren, and A. Brahme, Tumor and normal tissue responses to fractionated non uniform dose delivery. International Journal of Radiation Biology 1992. 62(2): p. 249-262.
[37] International Commission on Radiation Units and Measurements (ICRU) Report 50, Prescribing, Recording, and Reporting Photon Beam Therapy 1993: Bethesda, MD, USA.
[38] International Commission on Radiation Units and Measurements (ICRU) Report 62, Prescribing, Recording, and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). 1999: Bethesda, MD, USA.
[39] McKenzie, A., M. van Herk, and B. Mijnheer, Margins for geometric uncertainty around organs at risk in radiotherapy. Radiotherapy Oncology, 2002. 62: p. 299-307.
[40] Muren, L.P., R. Ekerold, and Y. Kvinnsland, On the use of margins for geometrical uncertainties around the rectum in radiotherapy planning. Radiotherapy Oncology, 2004. 70: p. 11-19.
[41] Stroom, J.C. and B.J.M. Heijmen, Limitations of the planning organ at risk volume (PRV) concept. International Journal of Radiation Oncology Biology Physics, 2006. 66(1): p. 279-286.
[42] Goitien, M., M. Abrahams, and D.R. Rowell, Multidimensional treatment planning: II. Beam's eye view, back projection, and projection through CT sections. International Journal of Radiation Oncology Biology Physics, 1983. 9: p. 789-797.
[43] Bortfeld, T., IMRT: a review and preview. Physics in Medicine and Biology, 2006. 51: p. R363-R379.
[44] Boyer, A.L., Intensity modulated radiation therapy, in Treatment Planning In Radiation Oncology, F.M. Khan, Editor. 2007, Lippincott Williams & Wilkins: Philadelphia, PA, USA. p. 142-165.
[45] Intensity Modulated Radiation Therapy Collaborative Working Group, Intensity-modulated radiotherapy: current status and issues of interest. International Journal of Radiation Oncology Biology Physics, 2001. 51(4): p. 880-914.
[46] Purdy, J.A., The development of intensity modulated radiation therapy, in The Theory & Practice of Intensity Modulated Radiation Therapy, E.S. Sternick, and Editor. 1997, Advanced Medical Publishing: Madison, WI, USA. p. 1-15.
[47] Peterson, L., Intensity modulated radiation therapy update. Trends in Medicine, 2003. March: p. 1-3.
[48] Purdy, J.A., Volume and dose specification for three-dimensional conformal radiotherapy. , in 3D Radiation Treatment Planning and Conformal Therapy, J.A. Purdy and B. Emami, Editors. 1995, Medical Physics Publishing: Madison, Wisconsin, USA. p. 11-14.
[49] Purdy, J.A., Dose volume specification: new challenges with intensitymodulated radiation therapy Seminars in Radiation Oncology, 2002. 12: p. 199-209.
[50] Lof, J., Development of a general framework for optimization of radiation therapy. 2000, Stockholm University: Stockholm.
[51] McAneney, H. and S.F.C. O'Rourke, Investigation of various growth mechanisms of solid tumor growth within the linear-quadratic model for radiotherapy. Physics in Medicine and Biology, 2007. 52: p. 1039-1054.
[52] Fowler, J.F., The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. . Acta Oncologica, 2005. 44: p. 265-276.
[53] Williams, S.G., et al., Use of individual fraction size data from 3756 patients to directly determine the a/b ratio of prostate cancer. . International Journal of Radiation Oncology Biology Physics, 2007. 68(1): p. 24-33.
[54] Garcia, L.M., D.E. Wilkins, and G.P. Raaphorst, a/b ratio: a dose range dependence study. International Journal of Radiation Oncology Biology Physics, 2007. 67(2): p. 587-593.
[55] Koukourakis, M.I., et al., Biological dose volume histograms during conformal hypofractionated accelerated radiotherapy for prostate cancer. Medical Physics, 2007. 34(1): p. 76-80.
[56] Brenner, D.J. and E.J. Hall, Fractionation and protraction for radiotherapy of prostate carcinoma. International Journal of Radiation Oncology Biology Physics, 1999. 43(5): p. 1095-1101.
[57] King, C.R. and C.S. Mayo, Letter to the Editor. Is the prostate a/b ratio of 1.5 from Benner and Hall a modeling artifact? International Journal of Radiation Oncology Biology Physics, 2000. 47(2): p. 536-539.
[58] King, C.R., T.A. DiPetrillo, and D.E. Wazer, Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. International Journal of Radiation Oncology Biology Physics, 2000. 46(1): p. 165-172.
[59] Fowler, J., R. Chappell, and M. Ritter, Is a/b for prostate tumors really low? International Journal of Radiation Oncology Biology Physics, 2001. 50(4): p. 1021-1031.
[60] King, C.R. and J.F. Fowler, A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. International Journal of Radiation Oncology Biology Physics, 2001. 51(1): p. 213-214.
[61] Brenner, D.J., et al., Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to lateresponding normal tissue. International Journal of Radiation Oncology Biology Physics, 2002. 52: p. 6-13.
[62] Wang, J.Z., M. Guerrero, and X.A. Li, How low is the a/b ratio for prostate cancer? . International Journal of Radiation Oncology Biology Physics, 2005. 55: p. 194-203.
[63] Kal, H.B. and M. P. van Gellekom, How low is the alpha/beta ratio for prostate cancer? International Journal of Radiation Oncology Biology Physics, 2003. 57: p. 1116-1121.
[64] Fowler, J.F., Development of radiobiology for oncology - a personal view. Physics in Medicine and Biology, 2006. 51: p. R263-R286.
[65] Nahum, A.E., et al., Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha/beta ratio. International Journal of Radiation Oncology Biology Physics, 2003. 57: p. 391-401.